MADD Canada et la Société des alcools de Terre-Neuve-et-Labrador font équipe pour présenter le nouveau Programme scolaire aux élèves de Terre-Neuve-et-Labrador
October 18, 2024 05:00 ET
|
MADD Canada
BAY ROBERTS, Terre-Neuve-et-Labrador, 18 oct. 2024 (GLOBE NEWSWIRE) -- MADD Canada est fier de lancer son Programme scolaire 2024-2025 en partenariat avec la Société des alcools de...
MADD Canada and NLC Team Up to Deliver New School Program to Newfoundland and Labrador Students
October 18, 2024 05:00 ET
|
MADD Canada
BAY ROBERTS, Newfoundland and Labrador, Oct. 18, 2024 (GLOBE NEWSWIRE) -- MADD Canada is proud to launch its 2024-2025 School Program in partnership with Newfoundland Labrador Liquor Corporation...
MADD Canada présente son nouveau Programme scolaire aux élèves de Terre-Neuve-et-Labrador
October 16, 2024 06:00 ET
|
MADD Canada
BAY ROBERTS, Terre-Neuve-et-Labrador, 16 oct. 2024 (GLOBE NEWSWIRE) -- MADD Canada annonce le lancement provincial de son nouveau Programme scolaire 2024-2025 qui sensibilise les jeunes aux...
MADD Canada Brings New School Program to Newfoundland and Labrador Students
October 16, 2024 06:00 ET
|
MADD Canada
BAY ROBERTS, Newfoundland and Labrador, Oct. 16, 2024 (GLOBE NEWSWIRE) -- MADD Canada is proud to announce the provincial launch of its 2024-2025 School Program which educates youth about the risks...
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
October 07, 2024 09:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Lifecore Biomedical Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology
October 01, 2024 07:00 ET
|
Lifecore Biomedical, Inc.
Multi-Million Dollar Development Agreement Establishes Lifecore as Lindy Biosciences’ Preferred CDMO Offers Lifecore Key Access Point into Manufacture and Fill/Finish of Next-Generation...
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging
September 18, 2024 11:07 ET
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presented on IRX4204 for treatment of brain aging, at the FASEB Conference on Cellular and Molecular Mechanisms of Brain Aging
Triamcinolone Market to Reach $1.3 Billion, Globally, by 2033 at 3.8% CAGR: Allied Market Research
September 18, 2024 06:28 ET
|
Allied Analytics LLP
Wilmington, Delaware, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Triamcinolone Market by Type (Cream, Injection and Inhalers), Application (Eczema,...
Deuxième cérémonie annuelle de MADD Canada en hommage aux victimes ontariennes de la conduite avec capacités affaiblies
September 14, 2024 07:00 ET
|
MADD Canada
BRAMPTON, Ontario, 14 sept. 2024 (GLOBE NEWSWIRE) -- Les familles et les amis des victimes tuées dans des collisions dues à l’alcool, au cannabis et/ou à d’autres drogues se rassembleront...
MADD Canada Holds Second Annual Ceremony for Ontario Victims of Impaired Driving
September 14, 2024 07:00 ET
|
MADD Canada
BRAMPTON, Ontario, Sept. 14, 2024 (GLOBE NEWSWIRE) -- Families and friends whose loved ones have been killed in alcohol, cannabis and/or other drug-related crashes will gather today for the second...